Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Letters to the Editor

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J et al. Autologous bone marrow transplantation in the treatment of poor prognosis non-Hodgkin's lymphomas. Eur J Cancer Clin Oncol 1984; 20: 217–2225.

    Article  CAS  Google Scholar 

  2. Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J et al. Non-Hodgkin's malignant lymphoma. Therapeutic value of autologous bone marrow transplantation. Presse Med 1983; 12: 1917–1923.

    CAS  PubMed  Google Scholar 

  3. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.

    Article  CAS  Google Scholar 

  4. Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010; 45: 1147–1153.

    Article  CAS  Google Scholar 

  5. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.

    Article  CAS  Google Scholar 

  6. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’slymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  Google Scholar 

  7. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting forlymphoma:resultsfrom the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020–1026.

    Article  CAS  Google Scholar 

  8. Sharma A, Kayal S, Iqbal S, Malik PS, Raina V . Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus 2013; 2: 489.

    Article  Google Scholar 

  9. Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  Google Scholar 

  10. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43–48.

    Article  CAS  Google Scholar 

  11. Jantunen E, Kuittinen T, Nousiainen T . BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151–1158.

    Article  CAS  Google Scholar 

  12. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004; 34: 581–587.

    Article  CAS  Google Scholar 

  13. Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant 2012; 10: 163–167.

    Article  Google Scholar 

Download references

Acknowledgements

KMA was supported by the UCL/UCLH Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Kothari.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kothari, J., Foley, M., Peggs, K. et al. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM. Bone Marrow Transplant 51, 1397–1399 (2016). https://doi.org/10.1038/bmt.2016.134

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.134

This article is cited by

Search

Quick links